Clincosm LogoSign in Get a demo

Multiple Myeloma, Refractory

Showing 1 - 22 of 22
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Venetoclax)

Not yet recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • (no location specified)
Oct 30, 2023

Alvocade® (Bortezomib) Safety and Effectiveness Study

Completed
  • Multiple Myeloma, Refractory
  • (no location specified)
Aug 19, 2023

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Carfilzomib, Cyclophosphamide, Dexamethasone)

Not yet recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • (no location specified)
Jun 8, 2023

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Anti-GPRC5D CAR-T Cells Injection)

Not yet recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Anti-GPRC5D CAR-T Cells Injection
  • (no location specified)
Feb 18, 2023

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Hangzhou (BCMA CAR-NK, Cyclophosphamide, Fludarabine

Recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • BCMA CAR-NK
  • +2 more
  • Hangzhou, Zhejiang, China
  • +1 more
Feb 17, 2023

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Kunming (Anti-GPRC5D CAR-T cells infusion)

Recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Anti-GPRC5D CAR-T cells infusion
  • Kunming, Yunnan, China
  • +1 more
Feb 21, 2023

Multiple Myeloma, Refractory, Multiple Myeloma in Relapse Trial in Cleveland (Autologous CAR-T cell therapy expressing the

Not yet recruiting
  • Multiple Myeloma, Refractory
  • Multiple Myeloma in Relapse
  • Autologous CAR-T cell therapy expressing the BAFF-ligand.
  • Cleveland, Ohio
    University Hospitals Seidman Cancer Center
Jan 11, 2023

Health Technology Intervention on Patient Activation in Multiple

Not yet recruiting
  • Multiple Myeloma in Relapse
  • +3 more
    • (no location specified)
    Jan 9, 2023

    Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Poitiers (Isatuximab, Carfilzomib, Pomalidomide)

    Active, not recruiting
    • Multiple Myeloma in Relapse
    • Multiple Myeloma, Refractory
    • Poitiers, France
      CHU Poitiers
    Jan 9, 2023

    Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma, Refractory Trial (Pomalidomide 4 mg every day in cycle 1,

    Not yet recruiting
    • Multiple Myeloma in Relapse
    • +2 more
    • Pomalidomide 4 mg every day in cycle 1
    • +4 more
    • (no location specified)
    Nov 16, 2022

    Long-term KRd in Relapsed and/or Refractory Multiple Myeloma

    Not yet recruiting
    • Multiple Myeloma in Relapse
    • Multiple Myeloma, Refractory
    • (no location specified)
    Aug 8, 2022

    Multiple Myeloma, Refractory Trial in Washington, Hackensack, Neptune (Pembrolizumab, Belantamab mafodotin, Dexamethasone)

    Not yet recruiting
    • Multiple Myeloma, Refractory
    • Washington, District of Columbia
    • +2 more
    Aug 5, 2022

    Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Hangzhou (APRIL CAR-T cells)

    Recruiting
    • Multiple Myeloma in Relapse
    • Multiple Myeloma, Refractory
    • APRIL CAR-T cells
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital，College of Medicine, Zhejiang Univ
    May 3, 2022

    Multiple Myeloma, Refractory Trial in Greece, Israel (Selinexor, Dexamethasone, Bortezomib)

    Recruiting
    • Multiple Myeloma, Refractory
    • Patra, Achaia, Greece
    • +15 more
    Apr 4, 2022

    Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in San Francisco (Pembrolizumab)

    Not yet recruiting
    • Multiple Myeloma
    • +4 more
    • Pembrolizumab
    • San Francisco, California
      University of California, San Francisco
    Mar 23, 2022

    Multiple Myeloma, Refractory, Hepatocarcinoma, Advanced Solid Tumor Trial in Catanzaro (LNA-i-miR-221)

    Completed
    • Multiple Myeloma, Refractory
    • +2 more
    • LNA-i-miR-221
    • Catanzaro, Italy
      Center for Phase I Clinical Studies in Medical Oncology and Onco
    Jan 31, 2022

    Multiple Myeloma, Refractory Trial in Chongqing (Anti-BCMA CAR-NK Cells, Fludarabine, Cytoxan)

    Recruiting
    • Multiple Myeloma, Refractory
    • Anti-BCMA CAR-NK Cells
    • +2 more
    • Chongqing, Chongqing, China
      Department of Hematology, Xinqiao Hospital
    Nov 21, 2021

    Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Wuhan (C-4-29 Cells)

    Enrolling by invitation
    • Multiple Myeloma in Relapse
    • Multiple Myeloma, Refractory
    • C-4-29 Cells
    • Wuhan, Hubei, China
      Union Hospital, Tongji Medical College, Huazhong University of S
    Aug 2, 2021

    Multiple Myeloma, Refractory, Multiple Myeloma in Relapse, Multiple Myeloma Trial in Boston (TEG002)

    Recruiting
    • Multiple Myeloma, Refractory
    • +2 more
    • TEG002
    • Boston, Massachusetts
    • +2 more
    Jul 9, 2021

    Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Tel Aviv (cyclosporine in combination with carfilzomib and

    Recruiting
    • Multiple Myeloma in Relapse
    • Multiple Myeloma, Refractory
    • cyclosporine in combination with carfilzomib and dexamethasone
    • Tel Aviv, Israel
      Tel Aviv Sourasky Medical Center
    Apr 19, 2021

    Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Acute Lymphoblastic Leukemia, in Relapse Trial in Hangzhou (CD19/BCMA

    Recruiting
    • Multiple Myeloma in Relapse
    • +5 more
    • CD19/BCMA Targeted CAR T-cells and dasatinib
    • CD19/BCMA Targeted CAR T-cells
    • Hangzhou, Zhejiang, China
      The First Hospital of Zhejiang Medical Colleage Zhejiang Univers
    Oct 27, 2020

    Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in New York (Pomalidomide, Cyclophosphamide, Dexamethasone)

    Completed
    • Multiple Myeloma in Relapse
    • Multiple Myeloma, Refractory
    • New York, New York
      Icahn School of Medicine at Mount Sinai
    Jun 14, 2019